• OPEN AN ACCOUNT
Indian Indices
Nifty
22,466.10 62.25
(0.28%)
Sensex
73,917.03 253.31
( 0.34%)
Bank Nifty
48,115.65 138.60
( 0.29%)
Nifty IT
33,381.85 -286.60
( -0.85%)
Global Indices
Nasdaq
16,698.32 -44.07
(-0.26%)
Dow Jones
39,869.38 -38.62
(-0.10%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.46 -0.04
(-0.05%)
EUR-INR
90.54 0.34
(0.38%)
GBP-INR
105.44 0.50
(0.48%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

ICICI Prudential Nifty 100 ETF
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
537008
INF109KC16V9
1
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NIF100IETF
0
71.52
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

titagarh rail systems ltd
Biocon jumps after receiving SAHPRA approval for Tacrolimus capsules
Apr 22,2024
Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients which reduces the body’s ability to reject a transplanted organ. It has been particularly effective in treating patients of renal transplant for more than two decades.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.